Q3 2022 13F Holders as of 9/30/2022
-
Type / Class
-
Equity / Common Stock
-
Shares outstanding
-
128M
-
Number of holders
-
84
-
Total shares
-
60.8M
-
Shares change
-
+8.11M
-
Total reported value, excl. options
-
$895M
-
Value change
-
+$128M
-
Number of buys
-
50
-
Number of sells
-
-29
-
Price
-
$14.72
Significant Holders of Cytek Biosciences, Inc. - Common Stock (CTKB) as of Q3 2022
84 filings reported holding CTKB - Cytek Biosciences, Inc. - Common Stock as of Q3 2022.
Cytek Biosciences, Inc. - Common Stock (CTKB) has 84 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 60.8M shares
of 128M outstanding shares and own 47.47% of the company stock.
Largest 10 shareholders include RA CAPITAL MANAGEMENT, L.P. (13.4M shares), HHLR ADVISORS, LTD. (8.76M shares), BlackRock Inc. (7.92M shares), VANGUARD GROUP INC (7.69M shares), BROWN CAPITAL MANAGEMENT LLC (4.41M shares), Blue Water Life Science Advisors, LP (2.1M shares), STATE STREET CORP (2.03M shares), GEODE CAPITAL MANAGEMENT, LLC (1.73M shares), Nuveen Asset Management, LLC (1.34M shares), and PERCEPTIVE ADVISORS LLC (1.29M shares).
This table shows the top 84 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.